Antiretrovirals Don't Increase Primary Central Lymphoma
Study shows a lower primary central nervous system lymphoma incidence in the HAART era
WEDNESDAY, Aug. 2 (HealthDay News) -- In HIV-positive patients, exposure to highly active antiretroviral therapy, or HAART, is not associated with an increased risk of primary central nervous system lymphoma (PCL), according to a report published in the Aug. 2 issue of the Journal of the National Cancer Institute.
Justin Stebbing, Ph.D., of The Chelsea and Westminster Hospital in London, U.K., and colleagues studied 9,621 HIV patients, including 3,748 from the pre-HAART era and 5,873 from the HAART era.
The researchers identified 61 patients with PCL who had a median survival of 1.3 months. They found a lower incidence of PCL in the HAART era (1.2 cases per 1,000 patient-years) than in the pre-HAART era (three cases per 1,000 patient-years) and longer overall survival (49 days versus 32 days).
"This is consistent with recent data that demonstrate a lack of class effect of antiretroviral agents in the prevention (or treatment) of systemic AIDS-related non-Hodgkin's lymphoma and AIDS-related Kaposi's sarcoma," the authors write.